康诺亚生物医药科技有限公司总部位于成都，专注研究创新单克隆抗体药物和其它治疗性蛋白药物研发与产业化，康诺亚于2021年7月8日在香港联合交易所主板上市。
Investors 1
| Date | Name | Website |
| - | 3H Health ... | 3hhinvestm... |
Mentions in press and media 12
| Date | Title | Description |
| 27.03.2024 | Keymed Biosciences Announces 2023 Annual Results and Business Updates | Submitted a New Drug Application (NDA) of Stapokibart (CM310) for the treatment of moderate-to-severe AD in adults. The NDA was accepted by the China's NMPA and granted priority review. Advanced a Phase III clinical study of Stapokibart for... |
| 15.05.2023 | Rona Therapeutics and Keymed Biosciences Announce Collaboration to Discover and Develop First-in-class siRNA Therapeutics for Glomerulonephritis | SHANGHAI, May 15, 2023 /PRNewswire/ -- Rona Therapeutics, Inc ("Rona") and Keymed Biosciences ("Keymed", HKEX: 02162), today announced a collaboration to jointly discover and develop first-in-class siRNA therapeutics for... |
| 18.03.2023 | Keymed Biosciences Announces 2022 Annual Results: Efficiently Promotes Clinical Progress & Proactively Develops Global Strategic Collaboration | CHENGDU, China, March 18, 2023 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) announced its 2022 annual results. Focused on unmet clinical needs, the Company continued to efficiently develop innovative and differentiated pipelines, p... |
| 18.03.2023 | Keymed Biosciences Announces 2022 Annual Results: Efficiently Promotes Clinical Progress & Proactively Develops Global Strategic Collaboration | CHENGDU, China, March 17, 2023 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) announced its 2022 annual results. Focused on unmet clinical needs, the Company continued to efficiently develop innovative and differentiated pipelines, p... |
| 23.02.2023 | Keymed and Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement with AstraZeneca for CMG901 | CHENGDU, China, Feb. 23, 2023 /PRNewswire/ -- Keymed Biosciences Inc., ("Keymed") (Stock Code: 02162 HK) and Lepu Biopharma Co., Ltd, (Stock Code: 02157.HK) today jointly announce a global exclusive licence agreement with AstraZen... |
| 18.01.2023 | Keymed Biosciences | The Latest Results from the Phase Ia Clinical Study of CMG901 was presented at the 2023 ASCO GI CANCERS SYMPOSIUM | CHENGDU, China, Jan. 18, 2023 /PRNewswire/ -- Keymed Biosciences Inc. (Stock Code: 02162 HK) is pleased to announce that the latest data from the Phase Ia dose-escalation trial of CMG901 (Claudin 18.2 antibody drug conjugate), a novel drug ... |
| 22.09.2022 | China CDE Grants CMG901 Breakthrough Therapy Designation for Claudin 18.2-Positive Advanced Gastric & Gastroesophageal Junction Cancer | CHENGDU, China, Sept. 22, 2022 /PRNewswire/ -- Keymed Biosciences (HKEX:02162) announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has granted CMG901 the Breakthrough Therapy Desi... |
| 10.06.2022 | Keymed Biosciences Announces Dosing of First Patient in Phase I Trial of Bispecific Antibody CM350 | CHENGDU, China, June 10, 2022 /PRNewswire/ -- Keymed Biosciences (HKEX: 02162) announced today that the first patient has been dosed in the Phase I trial of CM350. CM350 is a GPC3xCD3 bispecific antibody developed by the Company for the tre... |
| 20.04.2022 | FDA granted CMG901 Fast Track Designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies | CHENGDU, China, April 20, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that the U.S. Food and Drug Administration (FDA) granted CMG901 Fast Track Designation as monotherapy for the treatment of unresectable or metastatic gast... |
| 12.04.2022 | CMG901 for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma was granted the Orphan-drug Designation by the Food and Drug Administration of the United States | CHENGDU, China, April 12, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that its new drug candidate CMG901 (the "Claudin 18.2 antibody drug conjugates") for the treatment of gastric cancer and gastroesophageal juncti... |
Show more